iRadimed reports Q1 revenue up 13%, EPS growth, and declares $0.20 quarterly dividend

iRadimed Corporation reported a 13% revenue increase to $22 million in Q1 2026, driven by strong sales of MRI-compatible medical devices. GAAP diluted EPS rose 22% to $0.45, supported by disciplined expense management and a successful launch of the next-gen 3870 IV infusion pump. The company declared a $0.20 per share quarterly dividend and reaffirmed full-year 2026 guidance with expected revenue of $91-96 million and EPS growth. Positive early orders for the 3870 pump signal accelerating revenue growth in the second half of 2026.